UNSPSC 51162206: Camphor/eucalyptus oil/menthol/turpentine spirits

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE900. This VA Drug Class (RE900) classifies this compound as belonging to the group RESPIRATORY AGENTS, OTHER.

UNSPSC 51162206 Camphor/eucalyptus oil/menthol/turpentine spirits (Commodity) covers volatile organic compounds and topical analgesic oils procured by state and local health systems, correctional facilities, and public hospitals. State and local governments buy these products primarily as components in over-the-counter pain-relief preparations, inhalant therapies, and wound-care formulations distributed through pharmacy and medical supply chains. The procurement base spans state departments of health and human services, county health departments, and municipal hospital systems, though the recent activity reflects participation in cooperative purchasing vehicles that aggregate demand across multiple jurisdictions.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) on January 20, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products including compounds in this commodity family, with a response deadline of March 26, 2026. The contract will serve participating state and local government facilities across Minnesota and Oregon. Awarded vendors must supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and maintain relationships with at least two of the three. Products must be available by May 15, 2026, with resulting agreements effective July 1, 2026. Evaluation weights pricing competitiveness at 75 percent, with smaller weights for fixed pricing (10 percent), administrative compliance (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). Vendors must certify cGMP and Drug Supply Chain Security Act compliance, carry professional liability insurance of $2,000,000, and demonstrate flexible pricing options including flat price, net price formats, or WAC-minus structures.